Lymphoma and Myeloma Program

The Lymphoma and Myeloma Program characterizes specific lymphoid malignancies at both the cellular and molecular levels, using state-of-the-art approaches such as murine models and broad-based transcriptional and genetic profiling. In addition to gaining basic insight into pathogenetic mechanisms and predisposing factors, these efforts help identify relevant rational treatment targets.

The Program has a long-standing interest in analysis and augmentation of host immune response to lymphomas and myelomas. Recently, investigators have developed an extensive outcomes database and have begun to analyze long-term toxicity and quality-of-life issues in lymphoma and myeloma patients.

The Lymphoma and Myeloma Program has four specific aims:

• Determine the etiologies of specific lymphoid malignancies with emphasis on viral causes
• Elucidate pathogenetic mechanisms underlying specific lymphoid neoplasms, focusing on:
  • Informative chromosomal translocations and murine models
  • Abnormalities of signal transduction pathways
  • Interactions between the tumor and its microenvironment
• Develop novel therapeutic approaches to lymphoid malignancies, focusing on novel agents, risk-related therapy, high dose therapy with autologous or allogeneic stem cell support, tumor immunity including graft versus lymphoma effects, and tumor cell vaccines
• Develop a comprehensive mechanism to analyze sociodemographic, clinical, treatment, and outcomes data on lymphoma patients.